Researchers published data in the British Journal of Cancer suggesting whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes in advanced ovarian cancer after neoadjuvant chemotherapy. The study centers on post-NACT imaging signals intended to forecast response and downstream disease control. If validated in larger cohorts, WB-DWI/MRI could streamline risk stratification by offering a whole-body assessment rather than relying solely on site-specific imaging and biomarkers. In ovarian cancer, where disease distribution can be patchy, a systemic imaging approach may better capture residual disease dynamics. For clinical teams, the immediate value is potential earlier identification of patients less likely to benefit from standard post-NACT pathways, enabling more tailored follow-on decisions.